Jazz Pharmaceuticals JAZZ Maximum secured leverage ratio, for restricted payments to be allowed
Maximum secured leverage ratio, for restricted payments to be allowed at other companies
Other financials
Where this comes from
Reported directly by Jazz Pharmaceuticals in its filing.
Tagged under the XBRL concept jazz:DebtInstrumentCovenantMaximumSecuredLeverageRatioForRestrictedPaymentsToBeAllowed.
The official record: Jazz Pharmaceuticals’s 10-K, filed February 24, 2026, on SEC EDGAR. View the filing →
Ask your AI about Jazz Pharmaceuticals's maximum secured leverage ratio, for restricted payments to be allowed.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Jazz Pharmaceuticals's maximum secured leverage ratio, for restricted payments to be allowed?
- Jazz Pharmaceuticals (JAZZ) reported maximum secured leverage ratio, for restricted payments to be allowed of 500% in Q4 2025.
- How has Jazz Pharmaceuticals's maximum secured leverage ratio, for restricted payments to be allowed changed year-over-year?
- Jazz Pharmaceuticals's maximum secured leverage ratio, for restricted payments to be allowed decreased by 0.0% year-over-year, from 500% to 500%.
- What does maximum secured leverage ratio, for restricted payments to be allowed mean?
- The highest level of secured debt relative to earnings allowed before triggering covenant restrictions.
- How do you interpret maximum secured leverage ratio, for restricted payments to be allowed?
- A higher threshold provides more operational breathing room, while a lower threshold indicates a more restrictive credit environment.
- How does maximum secured leverage ratio, for restricted payments to be allowed compare across companies?
- Commonly used in credit agreements across the pharmaceutical and biotech sectors to manage leverage risk.